drugset / Trial / NCT02210806

Albuterol DPI (A006) Clinical Study-B3:Efficacy, Dose-ranging and Safety Evaluation

NCT02210806

Phase 2 Completed 22 enrolled Amphastar Pharmaceuticals, Inc.
RandomizedCrossoverQuadruple-blindTreatment

Summary

This study evaluates the efficacy, dose-ranging and safety profiles of A006, an Albuterol dry powder inhaler (DPI), in the dose range of 110 to 220 mcg per dose in comparison to a DPI Placebo Control and an Albuterol metered dose inhaler (MDI) Active Control.

Timeline

Start
2014-07
Primary completion
2014-09
Completion
2014-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Salbutamol Unknown 90 ug Inhaled
Comparator Salbutamol Unknown 110 ug Inhaled
Comparator Salbutamol Unknown 220 ug Inhaled

Indications